{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:34:48Z","timestamp":1790602488839,"version":"4.1.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T00:00:00Z","timestamp":1540166400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T00:00:00Z","timestamp":1540166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA172631"],"award-info":[{"award-number":["R01CA172631"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R15CA176648"],"award-info":[{"award-number":["R15CA176648"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Arkansas Breast Cancer Research Programs"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13058-018-1054-3","type":"journal-article","created":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T11:47:42Z","timestamp":1540208862000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines"],"prefix":"10.1186","volume":"20","author":[{"given":"Sruthi","family":"Ravindranathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khue G.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha L.","family":"Kurtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haven N.","family":"Frazier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean G.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhanu prasanth","family":"Koppolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narasimhan","family":"Rajaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6885-6727","authenticated-orcid":false,"given":"David A.","family":"Zaharoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,22]]},"reference":[{"issue":"1","key":"1054_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. Ca-Cancer J Clin. 2018;68(1):7\u201330.","journal-title":"Ca-Cancer J Clin"},{"issue":"8","key":"1054_CR2","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrc1670","volume":"5","author":"B Weigelt","year":"2005","unstructured":"Weigelt B, Peterse JL, van \u2019t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591\u2013602.","journal-title":"Nat Rev Cancer"},{"issue":"16","key":"1054_CR3","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/jnci\/djn233","volume":"100","author":"AM Brewster","year":"2008","unstructured":"Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008;100(16):1179\u201383.","journal-title":"J Natl Cancer Inst"},{"key":"1054_CR4","doi-asserted-by":"publisher","first-page":"f385","DOI":"10.1136\/bmj.f385","volume":"346","author":"M Baum","year":"2013","unstructured":"Baum M. Harms from breast cancer screening outweigh benefits if death caused by treatment is included. BMJ. 2013;346:f385.","journal-title":"BMJ"},{"issue":"10","key":"1054_CR5","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1172\/JCI20312","volume":"113","author":"S Baskar","year":"2004","unstructured":"Baskar S, Kobrin CB, Kwak LW. Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. J Clin Invest. 2004;113(10):1498\u2013510.","journal-title":"J Clin Invest"},{"issue":"12","key":"1054_CR6","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1158\/1078-0432.CCR-15-2163","volume":"22","author":"WT Curry Jr","year":"2016","unstructured":"Curry WT Jr, Gorrepati R, Piesche M, Sasada T, Agarwalla P, Jones PS, Gerstner ER, Golby AJ, Batchelor TT, Wen PY, et al. Vaccination with irradiated autologous tumor cells mixed with irradiated GM-K562 cells stimulates antitumor immunity and T lymphocyte activation in patients with recurrent malignant glioma. Clin Cancer Res. 2016;22(12):2885\u201396.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1054_CR7","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00262-008-0536-z","volume":"57","author":"TD de Gruijl","year":"2008","unstructured":"de Gruijl TD, van den Eertwegh AJ, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother. 2008;57(10):1569\u201377.","journal-title":"Cancer Immunol Immunother"},{"issue":"17\u201319","key":"1054_CR8","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1016\/S0264-410X(00)00485-0","volume":"19","author":"MG Hanna Jr","year":"2001","unstructured":"Hanna MG Jr, Hoover HC Jr, Vermorken JB, Harris JE, Pinedo HM. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine. 2001;19(17\u201319):2576\u201382.","journal-title":"Vaccine"},{"issue":"35","key":"1054_CR9","doi-asserted-by":"publisher","first-page":"8978","DOI":"10.1200\/JCO.2005.01.6816","volume":"23","author":"RM Luiten","year":"2005","unstructured":"Luiten RM, Kueter EWM, Mooi W, Gallee MPW, Rankin EM, Gerritsen WR, Clift SM, Nooijen WJ, Weder P, van de Kasteele WF, et al. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol. 2005;23(35):8978\u201391.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1054_CR10","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.4049\/jimmunol.169.6.3407","volume":"169","author":"J Manne","year":"2002","unstructured":"Manne J, Mastrangelo MJ, Sato T, Berd D. TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine. J Immunol. 2002;169(6):3407\u201312.","journal-title":"J Immunol"},{"issue":"1","key":"1054_CR11","first-page":"72","volume":"1865","author":"E Ophir","year":"2016","unstructured":"Ophir E, Bobisse S, Coukos G, Harari A, Kandalaft LE. Personalized approaches to active immunotherapy in cancer. Biochim Biophys Acta. 2016;1865(1):72\u201382.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"1054_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/PPO.0b013e3182337a76","volume":"17","author":"G Parmiani","year":"2011","unstructured":"Parmiani G, Pilla L, Maccalli C, Russo V. Autologous versus allogeneic cell-based vaccines? Cancer J. 2011;17(5):331\u20136.","journal-title":"Cancer J"},{"key":"1054_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/978-0-387-72005-0_37","volume":"601","author":"PL Thompson","year":"2007","unstructured":"Thompson PL, Dessureault S. Tumor cell vaccines. Adv Exp Med Biol. 2007;601:345\u201355.","journal-title":"Adv Exp Med Biol"},{"key":"1054_CR14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2147\/OTT.S92182","volume":"9","author":"S Wittke","year":"2016","unstructured":"Wittke S, Baxmann S, Fahlenkamp D, Kiessig ST. Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine. Oncotargets Ther. 2016;9:523\u201337.","journal-title":"Oncotargets Ther"},{"key":"1054_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.semcdb.2016.08.025","volume":"64","author":"RE Ellsworth","year":"2017","unstructured":"Ellsworth RE, Blackburn HL, Shriver CD, Soon-Shiong P, Ellsworth DL. Molecular heterogeneity in breast cancer: state of the science and implications for patient care. Semin Cell Dev Biol. 2017;64:65\u201372.","journal-title":"Semin Cell Dev Biol"},{"key":"1054_CR16","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.breast.2015.07.009","volume":"24","author":"BD Lehmann","year":"2015","unstructured":"Lehmann BD, Pietenpol JA. Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast. 2015;24:S36\u201340.","journal-title":"Breast"},{"issue":"1","key":"1054_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10549-017-4113-z","volume":"162","author":"D Ma","year":"2017","unstructured":"Ma D, Jiang YZ, Liu XY, Liu YR, Shao ZM. Clinical and molecular relevance of mutant-allele tumor heterogeneity in breast cancer. Breast Cancer Res Treat. 2017;162(1):39\u201348.","journal-title":"Breast Cancer Res Treat"},{"key":"1054_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/978-1-4939-3347-1_8","volume":"1395","author":"S Braga","year":"2016","unstructured":"Braga S. Resistance to targeted therapies in breast cancer. Methods Mol Biol. 2016;1395:105\u201336.","journal-title":"Methods Mol Biol."},{"issue":"9 Supplement","key":"1054_CR19","doi-asserted-by":"publisher","first-page":"P1-04-04-P1-04-","DOI":"10.1158\/1538-7445.SABCS14-P1-04-04","volume":"75","author":"Wen-Jia Zuo","year":"2015","unstructured":"Zuo WJ, Jiang YZ, Yu KD, Shao ZM. Activating HER2 mutations promote oncogenesis and resistance to HER2-targeted therapies in breast cancer. Cancer Res. 2015;75.","journal-title":"Cancer Research"},{"issue":"6024","key":"1054_CR20","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565\u201370.","journal-title":"Science"},{"issue":"4","key":"1054_CR21","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","volume":"21","author":"GL Beatty","year":"2015","unstructured":"Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21(4):687\u201392.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1054_CR22","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.leukres.2009.12.013","volume":"34","author":"MT Litzinger","year":"2010","unstructured":"Litzinger MT, Foon KA, Tsang KY, Schlom J, Palena C. Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells. Leukemia Res. 2010;34(10):1351\u20137.","journal-title":"Leukemia Res"},{"issue":"10","key":"1054_CR23","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/cgt.2010.29","volume":"17","author":"RK Sharma","year":"2010","unstructured":"Sharma RK, Yolcu ES, Elpek KG, Shirwan H. Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy. Cancer Gene Ther. 2010;17(10):730\u201341.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"1054_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/imm.12477","volume":"146","author":"M Mazzocco","year":"2015","unstructured":"Mazzocco M, Martini M, Rosato A, Stefani E, Matucci A, Dalla Santa S, De Sanctis F, Ugel S, Sandri S, Ferrarini G, et al. Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma. Immunology. 2015;146(1):33\u201349.","journal-title":"Immunology"},{"issue":"10","key":"1054_CR25","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/eji.1830251004","volume":"25","author":"J Sule-Suso","year":"1995","unstructured":"Sule-Suso J, Arienti F, Melani C, Colombo MP, Parmiani G. A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes. Eur J Immunol. 1995;25(10):2737\u201342.","journal-title":"Eur J Immunol"},{"issue":"1","key":"1054_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/CJI.0b013e31815ba792","volume":"31","author":"M Fishman","year":"2008","unstructured":"Fishman M, Hunter TB, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo MJ, Noyes DR, Mahany JJ, Lee JH, et al. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J Immunother. 2008;31(1):72\u201380.","journal-title":"J Immunother"},{"key":"1054_CR27","doi-asserted-by":"publisher","first-page":"8121985","DOI":"10.1155\/2016\/8121985","volume":"2016","author":"M Lotem","year":"2016","unstructured":"Lotem M, Merims S, Frank S, Hamburger T, Nissan A, Kadouri L, Cohen J, Straussman R, Eisenberg G, Frankenburg S, et al. Adjuvant autologous melanoma vaccine for macroscopic stage III disease: survival, biomarkers, and improved response to CTLA-4 blockade. J Immunol Res. 2016;2016:8121985.","journal-title":"J Immunol Res"},{"issue":"11","key":"1054_CR28","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1200\/JCO.1990.8.11.1858","volume":"8","author":"D Berd","year":"1990","unstructured":"Berd D, Maguire HC Jr, McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol. 1990;8(11):1858\u201367.","journal-title":"J Clin Oncol"},{"issue":"45","key":"1054_CR29","doi-asserted-by":"publisher","first-page":"74107","DOI":"10.18632\/oncotarget.12316","volume":"7","author":"KH Pyo","year":"2016","unstructured":"Pyo KH, Lee YW, Lim SM, Shin EH. Immune adjuvant effect of a Toxoplasma gondii profilin-like protein in autologous whole-tumor-cell vaccination in mice. Oncotarget. 2016;7(45):74107\u201319.","journal-title":"Oncotarget"},{"key":"1054_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.vetimm.2016.10.011","volume":"182","author":"JR Yannelli","year":"2016","unstructured":"Yannelli JR, Wouda R, Masterson TJ, Avdiushko MG, Cohen DA. Development of an autologous canine cancer vaccine system for resectable malignant tumors in dogs. Vet Immunol Immunop. 2016;182:95\u2013100.","journal-title":"Vet Immunol Immunop"},{"issue":"1","key":"1054_CR31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1158\/1078-0432.CCR-10-2195","volume":"17","author":"J Olivares","year":"2011","unstructured":"Olivares J, Kumar P, Yu Y, Maples PB, Senzer N, Bedell C, Barve M, Tong A, Pappen BO, Kuhn J, et al. Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin Cancer Res. 2011;17(1):183\u201392.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1054_CR32","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1586\/14760584.2014.911093","volume":"13","author":"L Cicchelero","year":"2014","unstructured":"Cicchelero L, de Rooster H, Sanders NN. Various ways to improve whole cancer cell vaccines. Expert Rev Vaccines. 2014;13(6):721\u201335.","journal-title":"Expert Rev Vaccines"},{"issue":"17","key":"1054_CR33","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1200\/JCO.2003.07.005","volume":"21","author":"R Soiffer","year":"2003","unstructured":"Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol. 2003;21(17):3343\u201350.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1054_CR34","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1158\/1078-0432.CCR-14-2932","volume":"21","author":"JM Goldberg","year":"2015","unstructured":"Goldberg JM, Fisher DE, Demetri GD, Neuberg D, Allsop SA, Fonseca C, Nakazaki Y, Nemer D, Raut CP, George S, et al. Biologic activity of autologous, granulocyte-macrophage colony-stimulating factor secreting alveolar soft-part sarcoma and clear cell sarcoma vaccines. Clin Cancer Res. 2015;21(14):3178\u201386.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1054_CR35","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.3892\/mmr.2014.2474","volume":"10","author":"X Chen","year":"2014","unstructured":"Chen X, Ni J, Meng H, Li D, Wei Y, Luo Y, Wu Y. Interleukin15: a potent adjuvant enhancing the efficacy of an autologous wholecell tumor vaccine against Lewis lung carcinoma. Mol Med Rep. 2014;10(4):1828\u201334.","journal-title":"Mol Med Rep"},{"issue":"4","key":"1054_CR36","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1200\/JCO.2003.03.091","volume":"21","author":"R Salgia","year":"2003","unstructured":"Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003;21(4):624\u201330.","journal-title":"J Clin Oncol"},{"issue":"20","key":"1054_CR37","first-page":"5160","volume":"59","author":"JW Simons","year":"1999","unstructured":"Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 1999;59(20):5160\u20138.","journal-title":"Cancer Res"},{"issue":"3","key":"1054_CR38","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1158\/2326-6066.CIR-16-0162","volume":"5","author":"AA Alkayyal","year":"2017","unstructured":"Alkayyal AA, Tai LH, Kennedy MA, de Souza CT, Zhang JQ, Lefebvre C, Sahi S, Ananth AA, Mahmoud AB, Makrigiannis AP, et al. NK-cell recruitment is necessary for eradication of peritoneal carcinomatosis with an IL12-expressing Maraba virus cellular vaccine. Cancer Immunol Res. 2017;5(3):211\u201321.","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"1054_CR39","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1038\/mt.2016.86","volume":"24","author":"M Ghisoli","year":"2016","unstructured":"Ghisoli M, Barve M, Mennel R, Lenarsky C, Horvath S, Wallraven G, Pappen BO, Whiting S, Rao D, Senzer N, et al. Three-year follow up of GMCSF\/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy (Vigil) in metastatic advanced Ewing's sarcoma. Mol Ther. 2016;24(8):1478\u201383.","journal-title":"Mol Ther"},{"issue":"2","key":"1054_CR40","doi-asserted-by":"publisher","first-page":"735","DOI":"10.4049\/jimmunol.1400004","volume":"193","author":"L Zhao","year":"2014","unstructured":"Zhao L, Mei Y, Sun Q, Guo L, Wu Y, Yu X, Hu B, Liu X, Liu H. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response. J Immunol. 2014;193(2):735\u201345.","journal-title":"J Immunol"},{"issue":"9","key":"1054_CR41","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1097\/CJI.0b013e3181869893","volume":"31","author":"HV Russell","year":"2008","unstructured":"Russell HV, Strother D, Mei Z, Rill D, Popek E, Biagi E, Yvon E, Brenner M, Rousseau R. A phase 1\/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. J Immunother. 2008;31(9):812\u20139.","journal-title":"J Immunother"},{"issue":"5","key":"1054_CR42","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00262-009-0784-6","volume":"59","author":"M May","year":"2010","unstructured":"May M, Brookman-May S, Hoschke B, Gilfrich C, Kendel F, Baxmann S, Wittke S, Kiessig ST, Miller K, Johannsen M. Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol Immun. 2010;59(5):687\u201395.","journal-title":"Cancer Immunol Immun"},{"issue":"4","key":"1054_CR43","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/jnci\/djh028","volume":"96","author":"J Nemunaitis","year":"2004","unstructured":"Nemunaitis J, Sterman D, Jablons D, Smith JW 2nd, Fox B, Maples P, Hamilton S, Borellini F, Lin A, Morali S, et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst. 2004;96(4):326\u201331.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"1054_CR44","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1200\/JCO.1997.15.4.1354","volume":"15","author":"T Ahlert","year":"1997","unstructured":"Ahlert T, Sauerbrei W, Bastert G, Ruhland S, Bartik B, Simiantonaki N, Schumacher J, Hacker B, Schumacher M, Schirrmacher V. Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. J Clin Oncol. 1997;15(4):1354\u201366.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1054_CR45","first-page":"495","volume":"15","author":"XP Jiang","year":"2000","unstructured":"Jiang XP, Yang DC, Elliott RL, Head JF. Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125 - Results in immune and clinical responses in breast cancer patients. Cancer Biother Radio. 2000;15(5):495\u2013505.","journal-title":"Cancer Biother Radio"},{"issue":"3","key":"1054_CR46","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.suronc.2013.05.003","volume":"22","author":"RL Elliott","year":"2013","unstructured":"Elliott RL, Head JF. Adjuvant breast cancer vaccine improves disease specific survival of breast cancer patients with depressed lymphocyte immunity. Surg Oncol. 2013;22(3):172\u20137.","journal-title":"Surg Oncol"},{"key":"1054_CR47","unstructured":"Vaccination with autologous breast cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) in metastatic breast cancer patients (NCT00317603). Available at: \n                    clinicaltrials.gov\n                    \n                  . Accessed 2 Aug 2017."},{"key":"1054_CR48","unstructured":"Autologous vaccination with lethally irradiated, autologous breast cancer cells engineered to secrete GM-CSF in women with operable breast cancer (NCT00880464). Available at: \n                    clinicaltrials.gov\n                    \n                  . Accessed 2 Aug 2017."},{"issue":"12","key":"1054_CR49","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1586\/14760584.2014.969714","volume":"13","author":"SL Kurtz","year":"2014","unstructured":"Kurtz SL, Ravindranathan S, Zaharoff DA. Current status of autologous breast tumor cell-based vaccines. Expert Rev Vaccines. 2014;13(12):1439\u201345.","journal-title":"Expert Rev Vaccines"},{"key":"1054_CR50","volume-title":"Frequently asked questions about mammography and the USPSTF recommendations: a guide for practitioners","author":"W Berg","year":"2009","unstructured":"Berg W, Hendrick E, Kopans D, Smith R. Frequently asked questions about mammography and the USPSTF recommendations: a guide for practitioners. Reston: Society of Breast Imaging; 2009."},{"issue":"5","key":"1054_CR51","first-page":"627","volume":"6","author":"DG Brockstedt","year":"2002","unstructured":"Brockstedt DG, Diagana M, Zhang Y, Tran K, Belmar N, Meier M, Yang A, Boissiere F, Lin A, Chiang Y. Development of anti-tumor immunity against a non-immunogenic mammary carcinoma through in vivo somatic GM-CSF, IL-2, and HSVtk combination gene therapy. Mol Ther. 2002;6(5):627\u201336.","journal-title":"Mol Ther"},{"issue":"7","key":"1054_CR52","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/sj.cgt.7700215","volume":"7","author":"AS Majumdar","year":"2000","unstructured":"Majumdar AS, Zolotorev A, Samuel S, Tran K, Vertin B, Hall-Meier M, Antoni B-A, Adeline E, Philip M, Philip R. Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model. Cancer Gene Ther. 2000;7(7):1086.","journal-title":"Cancer Gene Ther"},{"issue":"7","key":"1054_CR53","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/jnci\/85.7.546","volume":"85","author":"SJ Tsai","year":"1993","unstructured":"Tsai SJ, Gransbacher B, Tait L, Miller FR, Heppner GH. Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. JNCI. 1993;85(7):546\u201353.","journal-title":"JNCI"},{"issue":"11","key":"1054_CR54","doi-asserted-by":"publisher","first-page":"e113597","DOI":"10.1371\/journal.pone.0113597","volume":"9","author":"RM Gorczynski","year":"2014","unstructured":"Gorczynski RM, Chen Z, Erin N, Khatri I, Podnos A. Comparison of immunity in mice cured of primary\/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy. PLoS One. 2014;9(11):e113597.","journal-title":"PLoS One"},{"issue":"3","key":"1054_CR55","first-page":"735","volume":"49","author":"SC Rockwell","year":"1972","unstructured":"Rockwell SC, Kallman RF, Fajardo LF. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J Natl Cancer Inst. 1972;49(3):735\u201349.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"1054_CR56","first-page":"1941","volume":"59","author":"M Korbelik","year":"1999","unstructured":"Korbelik M, Dougherty GJ. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res. 1999;59(8):1941\u20136.","journal-title":"Cancer Res"},{"issue":"39","key":"1054_CR57","doi-asserted-by":"publisher","first-page":"64505","DOI":"10.18632\/oncotarget.11352","volume":"7","author":"D Shou","year":"2016","unstructured":"Shou D, Wen L, Song Z, Yin J, Sun Q, Gong W. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies. Oncotarget. 2016;7(39):64505.","journal-title":"Oncotarget"},{"issue":"2","key":"1054_CR58","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.3892\/ol.2017.6305","volume":"14","author":"K Gonda","year":"2017","unstructured":"Gonda K, Shibata M, Ohtake T, Matsumoto Y, Tachibana K, Abe N, Ohto H, Sakurai K, Takenoshita S. Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer. Oncol Lett. 2017;14(2):1766\u201374.","journal-title":"Oncol Lett"},{"issue":"6","key":"1054_CR59","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s00262-017-1977-z","volume":"66","author":"SM Toor","year":"2017","unstructured":"Toor SM, Khaja ASS, El Salhat H, Faour I, Kanbar J, Quadri AA, Albashir M, Elkord E. Myeloid cells in circulation and tumor microenvironment of breast cancer patients. Cancer Immunol Immunother. 2017;66(6):753\u201364.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1054_CR60","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10549-013-2618-7","volume":"140","author":"J Markowitz","year":"2013","unstructured":"Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WE. Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat. 2013;140(1):13\u201321.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1054_CR61","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","volume":"58","author":"CM Diaz-Montero","year":"2009","unstructured":"Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58(1):49\u201359.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"1054_CR62","doi-asserted-by":"publisher","first-page":"e32062","DOI":"10.1371\/journal.pone.0032062","volume":"7","author":"D Schaue","year":"2012","unstructured":"Schaue D, Ratikan JA, Iwamoto KS. Cellular autofluorescence following ionizing radiation. PLoS One. 2012;7(2):e32062.","journal-title":"PLoS One"},{"issue":"1","key":"1054_CR63","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/(SICI)1521-4141(199901)29:01<45::AID-IMMU45>3.0.CO;2-I","volume":"29","author":"MJ Deeths","year":"1999","unstructured":"Deeths MJ, Mescher MF. ICAM-1 and B7-1 provide similar but distinct costimulation for CD8+ T cells, while CD4+ T cells are poorly costimulated by ICAM-1. Eur J Immunol. 1999;29(1):45\u201353.","journal-title":"Eur J Immunol"},{"issue":"10","key":"1054_CR64","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nrc3581","volume":"13","author":"JE Talmadge","year":"2013","unstructured":"Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer. 2013;13(10):739\u201352.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1054_CR65","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","volume":"26","author":"DT Fisher","year":"2014","unstructured":"Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor microenvironment. Semin Immunol. 2014;26(1):38\u201347.","journal-title":"Semin Immunol"},{"issue":"4","key":"1054_CR66","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1124\/pr.56.4.3","volume":"56","author":"A Hoeben","year":"2004","unstructured":"Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56(4):549\u201380.","journal-title":"Pharmacol Rev"},{"issue":"21","key":"1054_CR67","doi-asserted-by":"publisher","first-page":"14542","DOI":"10.1074\/jbc.M802139200","volume":"283","author":"J Niu","year":"2008","unstructured":"Niu J, Azfer A, Zhelyabovska O, Fatma S, Kolattukudy PE. Monocyte chemotactic protein (MCP)-1 promotes angiogenesis via a novel transcription factor, MCP-1-induced protein (MCPIP). J Biol Chem. 2008;283(21):14542\u201351.","journal-title":"J Biol Chem"},{"issue":"6","key":"1054_CR68","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/00002371-200111000-00001","volume":"24","author":"V Bronte","year":"2001","unstructured":"Bronte V, Serafini P, Apolloni E, Zanovello P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother. 2001;24(6):431\u201346.","journal-title":"J Immunother"},{"issue":"1","key":"1054_CR69","doi-asserted-by":"publisher","first-page":"678","DOI":"10.4049\/jimmunol.166.1.678","volume":"166","author":"B Almand","year":"2001","unstructured":"Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001;166(1):678\u201389.","journal-title":"J Immunol"},{"issue":"4","key":"1054_CR70","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253\u201368.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"1054_CR71","doi-asserted-by":"publisher","first-page":"e27690","DOI":"10.1371\/journal.pone.0027690","volume":"6","author":"JD Waight","year":"2011","unstructured":"Waight JD, Hu Q, Miller A, Liu S, Abrams SI. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One. 2011;6(11):e27690.","journal-title":"PLoS One"},{"issue":"6","key":"1054_CR72","first-page":"1399","volume":"52","author":"CJ Aslakson","year":"1992","unstructured":"Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992;52(6):1399\u2013405.","journal-title":"Cancer Res"},{"issue":"5","key":"1054_CR73","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/bcr77","volume":"2","author":"GH Heppner","year":"2000","unstructured":"Heppner GH, Miller FR, Shekhar PM. Nontransgenic models of breast cancer. Breast Cancer Res. 2000;2(5):331\u20134.","journal-title":"Breast Cancer Res"},{"issue":"7","key":"1054_CR74","first-page":"1486","volume":"58","author":"BA Pulaski","year":"1998","unstructured":"Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 1998;58(7):1486\u201393.","journal-title":"Cancer Res"},{"issue":"2","key":"1054_CR75","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/annonc\/mdl158","volume":"18","author":"G Parmiani","year":"2007","unstructured":"Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol. 2007;18(2):226\u201332.","journal-title":"Ann Oncol"},{"key":"1054_CR76","first-page":"007","volume":"S2","author":"R Sivakumar","year":"2015","unstructured":"Sivakumar R, Atkinson MA, Mathews CE, Morel M. G-CSF: a friend or foe. Immunome Res. 2015;S2:007.","journal-title":"Immunome Res"},{"issue":"8","key":"1054_CR77","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/iub.361","volume":"62","author":"A Martins","year":"2010","unstructured":"Martins A, Han J, Kim SO. The multifaceted effects of granulocyte colony-stimulating factor in immunomodulation and potential roles in intestinal immune homeostasis. IUBMB Life. 2010;62(8):611\u20137.","journal-title":"IUBMB Life"},{"issue":"5","key":"1054_CR78","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.4049\/jimmunol.171.5.2637","volume":"171","author":"TD Eubank","year":"2003","unstructured":"Eubank TD, Galloway M, Montague CM, Waldman WJ, Marsh CB. M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J Immunol. 2003;171(5):2637\u201343.","journal-title":"J Immunol"},{"issue":"17","key":"1054_CR79","doi-asserted-by":"publisher","first-page":"6337","DOI":"10.1158\/0008-5472.CAN-04-0757","volume":"64","author":"P Serafini","year":"2004","unstructured":"Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004;64(17):6337\u201343.","journal-title":"Cancer Res"},{"issue":"50","key":"1054_CR80","doi-asserted-by":"publisher","first-page":"21248","DOI":"10.1073\/pnas.1015855107","volume":"107","author":"M Kowanetz","year":"2010","unstructured":"Kowanetz M, Wu X, Lee J, Tan M, Hagenbeek T, Qu X, Yu L, Ross J, Korsisaari N, Cao T, et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A. 2010;107(50):21248\u201355.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"1054_CR81","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1172\/JCI68189","volume":"123","author":"JD Waight","year":"2013","unstructured":"Waight JD, Netherby C, Hensen ML, Miller A, Hu Q, Liu S, Bogner PN, Farren MR, Lee KP, Liu KB, et al. Myeloid-derived suppressor cell development is regulated by a STAT\/IRF-8 axis. J Clin Investig. 2013;123(10):4464\u201378.","journal-title":"J Clin Investig"},{"issue":"11","key":"1054_CR82","doi-asserted-by":"publisher","first-page":"7085","DOI":"10.4049\/jimmunol.175.11.7085","volume":"175","author":"S Rutella","year":"2005","unstructured":"Rutella S, Zavala F, Danese S, Kared H, Leone G. Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. J Immunol. 2005;175(11):7085\u201391.","journal-title":"J Immunol"},{"issue":"7\u20138","key":"1054_CR83","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.intimp.2009.03.021","volume":"9","author":"MK Donkor","year":"2009","unstructured":"Donkor MK, Lahue E, Hoke TA, Shafer LR, Coskun U, Solheim JC, Gulen D, Bishay J, Talmadge JE. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. Int Immunopharmacol. 2009;9(7\u20138):937\u201348.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"1054_CR84","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1158\/0008-5472.CAN-14-2946","volume":"75","author":"S Agarwal","year":"2015","unstructured":"Agarwal S, Lakoma A, Chen Z, Hicks J, Metelitsa LS, Kim ES, Shohet JM. G-CSF promotes neuroblastoma tumorigenicity and metastasis via STAT3-dependent cancer stem cell activation. Cancer Res. 2015;75(12):2566\u201379.","journal-title":"Cancer Res"},{"key":"1054_CR85","first-page":"89","volume":"10","author":"RL Anderson","year":"2014","unstructured":"Anderson RL, Swierczak A, Cao Y, Hamilton JA. G-CSF promotes metastasis in preclinical models of breast cancer. Asia-Pac J Clin Onco. 2014;10:89\u201390.","journal-title":"Asia-Pac J Clin Onco"},{"issue":"5","key":"1054_CR86","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1186\/bcr3473","volume":"15","author":"K Oh","year":"2013","unstructured":"Oh K, Lee OY, Shon SY, Nam O, Ryu PM, Seo MW, Lee DS. A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. Breast Cancer Res. 2013;15(5):R79.","journal-title":"Breast Cancer Res"},{"issue":"8","key":"1054_CR87","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.4049\/jimmunol.0802740","volume":"182","author":"S Ostrand-Rosenberg","year":"2009","unstructured":"Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182(8):4499\u2013506.","journal-title":"J Immunol"},{"issue":"3","key":"1054_CR88","doi-asserted-by":"publisher","first-page":"e1115177","DOI":"10.1080\/2162402X.2015.1115177","volume":"5","author":"M Hollmen","year":"2016","unstructured":"Hollmen M, Karaman S, Schwager S, Lisibach A, Christiansen AJ, Maksimow M, Varga Z, Jalkanen S, Detmar M. G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer. Oncoimmunology. 2016;5(3):e1115177.","journal-title":"Oncoimmunology"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-018-1054-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13058-018-1054-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-018-1054-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T13:44:15Z","timestamp":1589550255000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-018-1054-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,22]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1054"],"URL":"https:\/\/doi.org\/10.1186\/s13058-018-1054-3","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,22]]},"assertion":[{"value":"2 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experiments involving laboratory animals were approved by the Institutional Animal Care and Use Committee at University of Arkansas.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"126"}}